AC 1204

Drug Profile

AC 1204

Alternative Names: AC-1204

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Accera
  • Class Antidementias; Triglycerides
  • Mechanism of Action Glucose stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 28 Feb 2017 Adverse events data from the phase III NOURISH AD trial in Alzheimer's disease released by Accera
  • 01 Dec 2016 Accera completes a phase I trial in Healthy volunteers in USA (NCT02833012)
  • 01 Nov 2016 Accera initiates a phase I bioequivalence trial in Healthy male volunteers in USA (PO) (NCT02959710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top